[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"locally-advanced-cervical-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:locally-advanced-cervical-cancers":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,71,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100610828","phase-2-iparomlimabtuvonralimab-injection-plus-ccrt-in-lacc-100610828",false,"NCT07232654","Iparomlimab\u002FTuvonralimab Injection Plus CCRT in LACC","A Clinical Study to Evaluate the Safety and Efficacy of Iparomlimab\u002FTuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer","Inclusion criteria\n\n* Informed consent.\n* Female patients aged ≥18 years and ≤ 75 years at time of inform consent signature\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Expected survival ≥ 3 months\n* Patients must have histologically confirmed diagnosis of HPV-related cervical squamous, or adenocarcinoma, or adenosquamous carcinoma\n* FIGO 2018 stage T3a-4a (III-IVA), N1 (positive lymph node metastasis on CT\u002FMRI with short-axis ≥1 cm, or PET-CT showing one or more lymph node metastases with SUVmax ≥2.5), M0\n* Has at least one evaluable disease per RECIST 1.1\n* Has adequate organ function\n\n  * Hematology: ANC ≥1.5 ×10⁹\u002FL; platelets ≥100 ×10⁹\u002FL; hemoglobin ≥90 g\u002FL (no blood transfusion or growth factor support within 7 days)\n  * Renal: CrCl ≥50 mL\u002Fmin (Cockcroft-Gault formula), urine protein \\\u003C2+ or 24h \\\u003C1.0 g\n  * Hepatic: Total bilirubin ≤1.5×ULN; AST and ALT ≤2.5×ULN\n  * Coagulation: INR and APTT ≤1.5×ULN\n  * Cardiac: LVEF ≥50%\n* Women of childbearing potential: a negative urine or serum pregnancy test within 3 days prior to the first dose of study drug (if the urine pregnancy test result cannot be confirmed as negative, a serum pregnancy test must be performed, and the serum result will be considered definitive).If a female participant of childbearing potential engages in sexual activity with a male partner who is not surgically sterile, she must use an acceptable method of contraception starting from screening and agree to continue using the same contraception for 120 days after the last dose of study drug. Whether to discontinue contraception after this period should be discussed with the investigator\n* Willingness to comply with the study procedures before study entry\n\nMain Exclusion Criteria:\n\n* Cervical cancer of other histology (e.g., neuroendocrine carcinoma, sarcoma)\n* Evidence of distant metastasis\n* Prior total hysterectomy (subtotal or cervical-sparing surgery allowed)\n* Unable or unwilling to receive brachytherapy\n* Prior treatment with immune checkpoint inhibitors or other tumor immunotherapy\n* Systemic corticosteroid (\\>10 mg\u002Fday prednisone or equivalent) or immunosuppressive therapy within 2 weeks (exceptions: inhaled\u002Ftopical ≤10 mg\u002Fday, physiologic replacement ≤10 mg\u002Fday, premedication for hypersensitivity).\n* Immunomodulatory drugs within 2 weeks (e.g., thymosin, interferons, IL-2)","FEMALE","18 Years","75 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is a clinical study to evaluate the safety and efficacy of Iparomlimab\u002FTuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer.",[27],"LOCALLY ADVANCED CERVICAL CANCERS",[29,30,31],"QL1706","Concurrent Chemoradiation Therapy","Cervical cancer","RECRUITING","2025-11-24",{"date":35,"type":36},"2025-12-01","ACTUAL",{"date":38,"type":36},"2025-11-11",{"date":40,"type":21},"2028-02-28",{"name":42,"class":43},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100611775","phase-2-neoadjuvant-ivonescimab-plus-chemotherapy-followed-by-concurrent-chemoradiotherapy-in-high-risk-locally-advanced-cervical-cancer-100611775","NCT07244965","Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer","Neoadjuvant Ivonescimab Combined With Paclitaxel and Cisplatin, Followed by Concurrent Chemoradiotherapy in Patients With High-Risk Locally Advanced Cervical Cancer：A Phase II, Single-Arm Study","Inclusion Criteria:\n\n* Able to understand and voluntarily sign the written informed consent form before any study-specific procedures.\n* Female participants aged ≥18 years on the day of signing informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Expected survival time ≥3 months.\n* Histologically confirmed diagnosis of cervical cancer.\n* Histological types limited to squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.\n* No prior anti-tumor treatments (including but not limited to radiotherapy, chemotherapy, surgery, targeted therapy, and immunotherapy). Note: Lymph node dissection or biopsy for clinical staging is allowed.\n* FIGO 2018 stage III-IVA cervical cancer unsuitable for curative surgery. Lymph node metastasis may be confirmed by biopsy or imaging. Imaging-based lymph node metastasis must meet: MRI\u002FCT showing positive lymph node with short-axis diameter ≥10 mm, and ≥15 mm to be used as target lesion.\n* At least one measurable lesion per RECIST v1.1 criteria.\n* PD-L1 CPS score ≥1 in tumor tissue.\n* Must provide tumor tissue sample before treatment (FFPE blocks or ≥5 unstained slides, preferably freshly obtained).\n* Adequate organ function as per screening labs:\n* Hematological (without transfusion or growth factors within 2 weeks):\n* ANC ≥1.5×10⁹\u002FL\n* Platelets ≥90×10⁹\u002FL\n* Hemoglobin ≥9.0 g\u002FdL\n* Renal:\n* Creatinine ≤1.5×ULN or CrCl ≥50 mL\u002Fmin (≥60 mL\u002Fmin if cisplatin is planned), calculated by Cockcroft-Gault:\n\nCrCl (mL\u002Fmin) = \\[(140 - age) × weight (kg) × 0.85\\] \u002F \\[serum creatinine (mg\u002FdL) × 72\\]\n\n* Hepatic:\n* Total bilirubin ≤1.5×ULN (≤3×ULN if Gilbert's syndrome suspected)\n* AST and ALT ≤2.5×ULN\n* Coagulation:\n* INR ≤1.5×ULN and APTT ≤1.5×ULN (unless on anticoagulants with stable dosing)\n* Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dose, and agree to use effective contraception during treatment and for at least 120 days after last dose of study drug and 180 days after chemoradiotherapy.\n* Effective contraception includes hormonal contraception, IUDs, or double barrier methods. Periodic abstinence and rhythm methods are not acceptable.\n\nExclusion Criteria:\n\n* Cervical cancer of non-eligible histology (e.g., neuroendocrine carcinoma, sarcoma).\n* Evidence of distant metastasis, including inguinal lymph node metastasis or lymph node involvement above L1 vertebral level.\n* History of total hysterectomy (removal of uterus and cervix). Subtotal hysterectomy or cornuostomy preserving the cervix is acceptable.\n* Anatomical or geometric contraindications to brachytherapy.\n* Active malignancies within 2 years, except for treated non-melanoma skin cancer, superficial bladder cancer, in-situ breast cancer (note: cervical carcinoma in situ history is exclusionary).\n* Bilateral hydronephrosis deemed non-relievable by nephrostomy or ureteral stenting.\n* Anti-tumor therapy within 2 weeks before treatment initiation (including but not limited to radiotherapy, chemotherapy, surgery, targeted therapy, immunotherapy, or immuno-co-stimulatory agents like ICOS, CD40, CD137, GITR, OX40 antibodies).\n* Immunomodulatory drugs (e.g., thymosin, interferon, IL-2) within 2 weeks before treatment.\n* Systemic corticosteroids (\\>10 mg\u002Fday prednisone or equivalent) or other immunosuppressants within 2 weeks, except:\n* Inhaled, ophthalmic, or topical steroids ≤10 mg\u002Fday prednisone or equivalent\n* Physiologic hormone replacement ≤10 mg\u002Fday prednisone or equivalent\n* Prophylactic corticosteroids for hypersensitivity (e.g., CT contrast)\n* Active infections requiring systemic treatment (e.g., active TB, syphilis, systemic fungal infections), except HBV antiviral therapy.\n* Severe infection within 4 weeks prior to treatment (e.g., hospitalization, sepsis, severe pneumonia).\n* Major surgery or significant trauma (e.g., fractures) within 4 weeks, or planned elective major surgery. Pelvic\u002Fpara-aortic lymph node dissection not exclusionary.\n* Live vaccines within 4 weeks.\n* Active or history of autoimmune diseases except for:\n* Vitiligo, alopecia, psoriasis, or eczema not requiring systemic therapy\n* Autoimmune thyroiditis requiring only stable hormone therapy\n* Type I diabetes requiring only stable insulin replacement\n* Any of the following cardiovascular\u002Fcerebrovascular diseases:\n* MI, unstable angina, PE, aortic dissection, DVT, or arterial embolism within 6 months\n* NYHA Class II or greater heart failure\n* Significant arrhythmias needing long-term treatment (stable asymptomatic Afib allowed)\n* Stroke (CVA) within 6 months\n* LVEF \\\u003C50%\n* History of myocarditis or cardiomyopathy\n* Known primary or secondary immunodeficiency, including HIV antibody positivity.\n* Active HBV infection: HBsAg positive with HBV DNA \\>1000 IU\u002FmL or \\>5000 copies\u002FmL; active HCV infection.\n* Exception: treated and stable HBV patients with HBV DNA ≤500 IU\u002FmL (or ≤2500 copies\u002FmL); cured HCV patients (HCVAb+ but HCV RNA-) allowed.\n* History of or active inflammatory bowel disease (Crohn's, ulcerative colitis), diverticulitis.\n* Known history of allogeneic organ or stem cell transplantation.\n* Interstitial lung disease or history of non-infectious pneumonitis.\n* History of severe hypersensitivity to monoclonal antibodies.\n* Known contraindications to cisplatin\u002Fcarboplatin or paclitaxel.\n* Pregnant or breastfeeding women.\n* Any condition that may interfere with the study drug's safety or efficacy evaluation as judged by the investigator (e.g., other serious illness, psychiatric disorders).",{"count":53,"type":21},42,[24],"This is a single-arm, phase II clinical trial evaluating the efficacy and safety of neoadjuvant Ivonescimab combined with paclitaxel and cisplatin (TP regimen), followed by concurrent chemoradiotherapy, in patients with high-risk, locally advanced cervical cancer (FIGO stage III-IVA). Eligible participants will receive two cycles of neoadjuvant Ivonescimab plus TP chemotherapy, followed by standard concurrent chemoradiotherapy. The primary endpoints include progression-free survival (PFS) and objective response rate (ORR) following neoadjuvant treatment. Secondary endpoints include overall survival (OS), disease control rate (DCR), safety, and quality of life (EORTC QLQ-C30). Exploratory analysis will focus on identifying predictive biomarkers for Ivonescimab efficacy.",[27],[58,59,60,61,62],"Ivonescimab","Cervical Cancer","Neoadjuvant","Immune Checkpoint Inhibitor","Concurrent Chemoradiotherapy","NOT_YET_RECRUITING","2025-11-20",{"date":33,"type":36},{"date":35,"type":21},{"date":68,"type":21},"2029-07-01",{"name":70,"class":43},"Women's Hospital School Of Medicine Zhejiang University",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100609349","outcomes-of-image-guided-high-dose-rate-uterovaginal-brachytherapy-with-single-implantation-100609349","NCT07213427","Outcomes of Image-guided High-dose-rate Uterovaginal Brachytherapy With Single Implantation","UNICURE-HD - Oncological and Functional Outcomes of Image-guided High-dose-rate Uterovaginal Brachytherapy With Single Implantation: a French Multicentre Study","UNICURE-HD","Inclusion Criteria:\n\n1. Women aged 18 years or older\n2. Diagnosis of locally advanced cervical cancer (squamous cell carcinoma, adenocarcinoma, or other)\n3. FIGO stage IB3-IV\n4. Treatment with chemoradiotherapy followed by uterovaginal brachytherapy with implantation in the operating room\n5. Informed and not opposed to the collection of her data for research purposes\n\nExclusion Criteria:\n\n1. Lack of information regarding follow-up\n2. Patient under legal protection measures -",{"count":80,"type":21},363,"OBSERVATIONAL","Background and Rationale:\n\nLocally advanced cervical cancer remains a major public health concern worldwide and in France. Standard-of-care management involves concurrent chemoradiotherapy followed by brachytherapy, which is critical for local tumour control and survival. Conventional high-dose-rate (HDR) brachytherapy protocols often require multiple implantations under anaesthesia, entailing increased logistical demands, operating room use, and patient discomfort.\n\nThe UNICURE-HD study investigates a simplified brachytherapy approach - a single intraoperative implantation delivering all planned fractions - combined with image guidance (MRI and\u002For CT) and 3D dosimetry, in order to assess whether it can maintain oncological outcomes while reducing treatment complexity and resource consumption.\n\nObjectives:\n\nPrimary objective: To evaluate local control at 3 and 5 years after completion of chemoradiotherapy and image-guided HDR uterovaginal brachytherapy with single implantation.\n\nSecondary objectives: To assess pelvic nodal control, para-aortic nodal control, distant control, progression-free survival, overall survival, and acute\u002Flate severe toxicities (CTCAE v5.0 ≥ grade 3). Prognostic factors will be analysed, and exploratory predictive models will be developed.\n\nStudy Design:\n\nThis is a retrospective, observational, multicentre study involving six French cancer centres (Pitié-Salpêtrière, Saint-Louis, Tenon, Institut de Cancérologie de Lorraine, Centre Oscar Lambret, CHU de La Réunion). Eligible patients are women ≥18 years, diagnosed with FIGO 2018 stage IB3-IV cervical cancer, treated between January 2014 and June 2024 with concurrent chemoradiotherapy followed by image-guided HDR uterovaginal brachytherapy using a single implantation.\n\nMethods:\n\nData will be extracted from medical records (electronic or paper), pseudonymised locally, and entered into a secure AP-HP-hosted database compliant with GDPR and the MR004 framework. Variables collected include demographics, tumour characteristics, EBRT details, brachytherapy technique (endocavitary vs hybrid\u002Finterstitial), dosimetric parameters (EQD2 for HR-CTV, IR-CTV, OARs), and outcomes. Imaging protocols, applicator types, and treatment times will also be recorded.\n\nStatistical analysis will use descriptive statistics, Kaplan-Meier survival estimation, log-rank tests, and multivariable Cox regression. Predictive models (LASSO, random forests) will be explored. Analyses will be conducted in R software.\n\nSample Size:\n\nApproximately 400 patients are expected, representing all eligible cases treated over the 10-year period in the participating centres.\n\nEthics and Regulatory Compliance:\n\nThe study follows GDPR and French data protection regulations (MR004). Ethics opinion has been requested from the Sorbonne Université Ethics Committee. Each centre will retain the correspondence table linking identifiers to pseudonyms locally; no directly identifying data will be shared.\n\nPotential Impact:\n\nIf the single-implantation HDR brachytherapy strategy achieves equivalent tumour control and toxicity profiles compared to multi-implant protocols, it could streamline cervical cancer management, reduce anaesthetic risk, improve patient comfort, and optimise resource use in high-volume oncology departments. This could have significant implications for accessibility and cost-effectiveness of cervical cancer care, particularly in settings with limited resources.",[27],[85,86,87,88,89],"Brachytherapy","gynaecologic","oncology","single-insertion","dosimetry","2025-10-01",{"date":92,"type":36},"2025-10-08",{"date":94,"type":21},"2025-12",{"date":96,"type":21},"2026-06",{"name":98,"class":43},"Assistance Publique - Hôpitaux de Paris",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100591548","phase-2-a-single-arm-exploratory-study-of-enlansibumab-sequentially-combined-with-concurrent-chemoradiotherapy-for-locally-advanced-cervical-cancer-100591548","NCT06981858","A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer","Inclusion criteria:\n\n1. Female, aged 18-70 years (including boundary values);\n2. Diagnosed histologically as cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma; 3.2018 FIGO stage IIB-IVA; Assess lymph node involvement based on one of the following criteria:\n\n   * Lymph node involvement confirmed by histology and biopsy;\n   * MRI or CT shows one or more positive pelvic\u002Fabdominal aortic lymph nodes with a minimum diameter of ≥ 15mm;\n   * PET\u002FCT or PET\u002FMR display one or more positive pelvic\u002Fabdominal aortic lymph nodes with SUVmax ≥ 2.5 and higher than the background value in surrounding normal tissues.\n\nAccording to the evaluation criteria for solid tumor efficacy version 1.1 (RECIST v1.1), having at least one measurable lesion; 5.ECOG PS 0-1； 6. According to the researcher's judgment, those with an expected survival period of ≥ 3 months; 7. The subjects can provide tumor tissue sections to determine whether formalin fixed paraffin embedded tumor histopathological samples or fresh tumor histopathological samples can be used for PD-L1 expression and other immune indicators detection; 8. Have sufficient organ function and meet the following laboratory examination standards:\n\n1. Blood routine (no blood transfusion within 14 days, no use of hematopoietic stimulating factors, and no use of other drugs to correct blood cell count): White blood cell count (WBC) ≥ 3000\u002Fmm3; Absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL; platelet count (PLT) ≥ 90 × 109\u002FL; hemoglobin (HGB) ≥ 9g\u002FdL;\n2. Blood biochemistry: creatinine (Cr) ≤ 1.5 × upper limit of normal (ULN), if\\>1.5 × ULN, creatinine clearance rate must be ≥ 60mL\u002Fmin, calculated using the Cockcroft Gault formula; Total bilirubin (TBIL) ≤ 1.5 × ULN; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN;\n3. Thyroid function: Thyroid stimulating hormone (TSH) ≤ ULN; If there are abnormalities, additional tests should be conducted on T3 and T4, and their levels should be normal; 9. Women of childbearing age who have a negative pregnancy test and are not breastfeeding, and have fertility, must receive effective medical contraception measures (from signing the informed consent form to within 6 months after the last study administration); 10. Participants must agree to collect blood samples, paraffin embedded (FFPE) tumor tissue specimens or sections, and fresh tumor tissue specimens for relevant research.\n\n11\\. The subjects voluntarily participated in this study, had good compliance with the planned treatment and follow-up, understood the research process of this study, and voluntarily signed an informed consent form.\n\nExclusion criteria:\n\n1. There are distant metastatic diseases present;\n2. Have received any previous anti-tumor treatment, including but not limited to surgery (excluding biopsy), radiotherapy, or systemic therapy (chemotherapy, immunotherapy, targeted therapy);\n3. Previous treatment with immune checkpoint inhibitors, including but not limited to other anti-PD-1 and anti-PD-L1 antibodies;\n4. Active malignant tumor within 3 years before the first administration, excluding cervical cancer studied in this trial and any locally curable tumor that has received radical treatment (such as excised basal cell or squamous cell skin cancer, superficial bladder cancer cancer or cured carcinoma in situ, such as breast carcinoma in situ);\n5. Suffering from active autoimmune diseases, or having a history of autoimmune diseases within 2 years before enrollment, and still requiring systemic treatment. Autoimmune diseases include but are not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, thyroid dysfunction, asthma requiring intervention with bronchodilators;\n6. Suffering from primary immunodeficiency disease or having a medical history;\n7. Individuals who have received immunosuppressive therapy (such as cyclosporine) or require systemic steroid therapy (such as\\>20 mg\u002Fday prednisone or equivalent) within the 14 days prior to enrollment, except for those who receive local corticosteroid therapy via nasal spray, inhalation, or other routes;\n8. Individuals who are HIV Ab positive or have active syphilis infection; Hepatitis B virus surface antigen (HBsAg) is positive, and the detection value of hepatitis B virus is\\>500IU\u002Fml or 2500 copies\u002FmL; Hepatitis C antibody (HCV Ab) is positive, and the hepatitis C virus RNA quantification is greater than the upper limit of the normal value of the detection unit. (Note: For those with positive hepatitis B virus surface antigen (HBsAg), antiviral treatment is recommended before the first use of the study drug, and nucleoside analogs such as entecavir and tenofovir dipivoxil are recommended. )\n9. Active bacterial, fungal, or viral infections (defined as requiring intravenous injection of antibacterial, antifungal, or antiviral drugs for treatment) within 14 days prior to enrollment. For individuals who have no clinical manifestations of active infection before the first medication and receive prophylactic treatment for infection, they may be considered for inclusion;\n10. Active tuberculosis or medical history;\n11. Have experienced severe cardiovascular disease within the 6 months prior to enrollment, including but not limited to: stable angina pectoris with functional classification of III-IV; Unstable angina or myocardial infarction; NYHA grade III-IV congestive heart failure; Severe arrhythmia requiring medication treatment (if ventricular rate can be controlled, asymptomatic atrial fibrillation subjects are allowed to be included); Serious arterial\u002Fvenous thrombotic events (such as cerebral hemorrhage, cerebral infarction, deep vein thrombosis, and pulmonary embolism);\n12. Suffering from uncontrollable hypertension;\n13. Have previously suffered from interstitial lung disease or non infectious pneumonia requiring glucocorticoid treatment;\n14. There is clinically significant hydronephrosis that cannot be relieved by nephrostomy or ureteral stent placement, as determined by researchers; Within 28 days prior to enrollment or planned to receive live or attenuated vaccine treatment during the study period;\n\n16\\. Known recipients of organ transplantation or allogeneic hematopoietic stem cell transplantation; 17. Have a history of severe allergic reactions and uncontrolled allergic asthma to all components of monoclonal antibody preparations; 18. There are contraindications or severe allergic reactions to any component of cisplatin; 19. Individuals who have participated in other clinical trials and used the investigational drug within 28 days prior to enrollment; 20. Participants who may have poor compliance with the research procedures and requirements, as determined by the researchers, such as those with a clear history of neurological or psychiatric disorders (including epilepsy or dementia), current mental disorders, and substance abuse; 21. Individuals with a clear history of neurological or mental disorders or drug abuse who are unable to quit or have a history of drug use; 22. There are situations where other researchers have determined that it is not suitable to participate in this experiment.","70 Years",{"count":107,"type":21},34,[24],"This is a prospective , single - arm clinical study , aiming to evaluate the efficacy and safety of Enlansibumab sequential concurrent chemoradiotherapy in locally advanced cervical cancer. Patients will first receive one cycle of Enlansibumab monotherapy (360 mg, 60 - min IV infusion on day 1, every 3 weeks). After one treatment cycle (3 weeks), they'll undergo imaging assessment. Then, they'll have Enlansibumab (360 mg, 60 - min IV infusion on day 1, every 3 weeks for two cycles) combined with concurrent chemoradiotherapy. Chemotherapy involves cisplatin (40 mg\u002Fm²) or carboplatin (AUC2) via IV infusion, weekly (±7 days), with five planned cycles. Investigators may add a sixth platinum - based chemotherapy cycle if needed. Radiotherapy comprises EBRT and BT and must be completed within eight weeks of treatment initiation. The total prescription dose of EBRT combined with BT should have an EQD2 of ≥8000 cGy, with adjustments based on tumor regression. After concurrent chemoradiotherapy, treatment ends. An imaging assessment occurs around seven days (±3 days) later. Then, the follow - up phase begins, including final, safety, and survival follow - ups, continuing until patients are lost to follow-up, the follow-up ends, or they die.",[27],"2025-05-13",{"date":113,"type":36},"2025-05-21",{"date":115,"type":21},"2025-05-15",{"date":117,"type":21},"2029-02-01",{"name":119,"class":43},"Chongqing University Cancer Hospital"]